MCC-950 is thus far the best investigated, direct, potent, selective and small-molecule inhibitor of NLRP3 and was shown to ameliorate NASH fibrosis [50] and liver damage in chronic stages of cholestasis in mice [24,48]. The gene discussed is NLRP3; the disease is metabolic dysfunction-associated steatohepatitis.